CLINICAL TRIAL SUMMARY

MDACC Study No:2009-0570 (clinicaltrials.gov NCT No: NCT01692197)
Title:A Phase 2 Study of E7070, Idarubicin and Cytarabine in Patients with Relapsed or Refractory Acute Myeloid Leukemia and High-risk Myelodysplastic Syndromes
Principal Investigator:Gautam Borthakur
Treatment Agent:Cytarabine; Dexamethasone; E7070; Idarubicin
Study Status:Open
Study Description:The goal of this clinical research study is to learn if E7070 in combination
with idarubicin, cytarabine, and dexamethasone can help to control the disease
in patients with either AML or high-risk MDS that has relapsed. The safety of
the drug combination will also be studied.

Hide details for General InformationGeneral Information

Disease Group:Leukemia
Phase of Study:Phase II
Treatment Agents:Cytarabine
Dexamethasone
E7070
Idarubicin
Treatment Location:Only at MDACC
Estimated Length of Stay in Houston:
Supported By:Eisai, Inc.
Return Visit:
Home Care:


Hide details for Study Contact InformationStudy Contact Information

Physician Name:Gautam Borthakur
Dept:Leukemia
For Clinical Trial Enrollment:713-563-1586
For General Questions about Clinical Trials:800-392-1611 (in U.S.A.) 713-792-6161 (outside U.S.A.)


Show details for Study Objectives / OutcomesStudy Objectives / Outcomes
Show details for Study Status InformationStudy Status Information
Show details for Enrollment EligibilityEnrollment Eligibility
Show details for Resources and LinksResources and Links
Show details for ResultsResults